The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis
The inclusion of evolocumab and alirocumab in the NRDLN has significantly enhanced their accessibility and eased the medication burden on patients. Furthermore, the disparity in the adoption and utilization of PCSK9 inhibitors across hospital tiers has progressively narrowed, thereby safeguarding equitable health outcomes and advancing population health security.
Authors
- Wei Lü (ORCID: https://orcid.org/0000-0003-3041-9200)
- Yan Fan (ORCID: https://orcid.org/0000-0002-8099-3203)
- Wei Li (ORCID: https://orcid.org/0000-0002-2295-2542)
- Anqi Zhang (ORCID: https://orcid.org/0000-0001-5128-2464)
- Huanhuan Wu (ORCID: https://orcid.org/0000-0002-8308-0872)
- Wan Tang (ORCID: https://orcid.org/0000-0001-7041-7715)
Institutions
- Xuzhou Medical College (CN)
- Shaanxi Xueqian Normal University (CN)
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.3389/fphar.2025.1612921
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00